Caliber ID's VivaScope technology found to be 100% sensitive for basal cell carcinoma diagnosis

ROCHESTER, N.Y., Sept. 13, 2012 /PRNewswire/ -- Caliber Imaging & Diagnostics, formerly Lucid, Inc. (OTCBB: LCDX), today announced that its VivaScope System using RCM technology was the subject of a recent report on a clinical study of more than 700 consecutive clinically equivocal cases. The research, reported in the Journal of Investigative Dermatology in July, found that for basal cell carcinoma (BCC), which is the most commonly diagnosed cancer in the world, using images captured with the VivaScope System achieved a sensitivity of 100% and a specificity of 88.5% (Guitera, 2012). The authors of the study further reported that the VivaScope System can "be used, in particular, to obtain quasi-histological diagnosis for BCCs and to follow efficacy of treatment."

In addition to studying BCC, the authors of this study found that the VivaScope System can reduce unnecessary surgical biopsies of benign lesions by as much as 68%. In this particular study, the physicians utilizing the VivaScope System yielded a sensitivity of 87.6% and a specificity of 70.8% for melanoma. The clinical model in the study yielded a sensitivity of 91.5% when considering all skin cancers (basal cell carcinoma, squamous cell carcinoma and melanoma).

The authors reported that, "the analysis of the cases in this study and the development of the RCM model for clinical diagnosis are based on the real clinical scenario faced by the dermatologist in the clinic where melanocytic and non-melanocytic lesions are mixed and only difficult cases are biopsied." The authors also confirmed that more accurate clinical diagnosis of skin tumors through the use of the Caliber ID VivaScope System is likely to improve patient management, reduce morbidity and mortality, and generate considerable economic benefits.

"Our VivaScope System allows physicians to rapidly and accurately detect and diagnose the most common cancer to affect mankind. This ability is just one of the things that sets this technology apart from many others," said L. Michael Hone, President and CEO at Caliber Imaging & Diagnostics. "With the advent of many noninvasive therapies, it doesn't make sense to have to diagnose the disease with an invasive test. With our VivaScope Systems, the physician is able to investigate the lesion, gain cellular resolution information and make an informed therapeutic decision, with no pain and no scarring for the patient."

The Skin Cancer Foundation reports, "BCC can be highly disfiguring if allowed to grow," (SkinCancer.org). According to a 2010 study by Rogers, et al., in the United States alone, an estimated 2.8 million cases of basal cell carcinoma are diagnosed each year. Further, the authors of that study report that, "Nonmelanoma skin cancer is the most common malignancy in the United States and is not reported in most registries; hence, the exact incidence is unknown. Based on the limited studies available, skin cancer rates seem to be climbing rapidly in the US population." Caliber ID's VivaScope System helps physicians to diagnose skin cancer and other diseases, at the bedside or remotely, by providing noninvasive and painless cellular resolution images of the skin's cells in their natural form.

About Caliber Imaging & Diagnostics

Caliber Imaging & Diagnostics' (Caliber ID) platform of products offer increased productivity from the doctor's office to the surgeon's operating room. Today, the future of skin cancer diagnosis is here: an integrated platform of tools and technology for accurate diagnoses quickly and routinely. Caliber ID products provide precise accuracy, consistent reliability, and online backup that all combine to lead to life-saving early diagnosis. Wherever you are in the continuum of skin imaging and diagnosis, this is not just best in class. This is a new class. For more information about Caliber ID and its products, please visit www.caliberid.com.

VivaScope^® is a registered trademark of Caliber Imaging & Diagnostics.

Safe Harbor

This press release contains "forward looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to our plans, objectives, expectations and intentions and other statements that contain words such as "expects," "contemplates," "anticipates," "plans," "intends," "believes," "assumes" and variations of such words or similar expressions that predict or indicate future events or trends, or that do not relate to historical matters. These statements are based on our current beliefs or expectations and are inherently subject to significant known and unknown uncertainties and changes in circumstances, many of which are beyond our control. There can be no assurance that our beliefs or expectations will be achieved and actual results may differ materially from our beliefs or expectations due to financial, economic, business, regulatory and other factors or conditions affecting us or our industry in general, as well as more specific risks and uncertainties facing us, such as those set forth in the Risk Factors section of the Forms 10-Q and 10-K filed by us with the SEC.

References:
Guitera, P., Menzies, S. W., Longo, C., Cesinaro, A. M., Scolyer, R. A., & Pellacani, G. (2012). In Vivo Confocal Microscopy for Diagnosis of Melanoma and Basal Cell Carcinoma Using a Two-Step Method: Analysis of 710 Consecutive Clinically Equivocal Cases. Journal of Investigative Dermatology. doi:10.1038/jid.2012.172

Basal Cell Carcinoma (BCC) – SkinCancer.org. Retrieved August 2, 2012, from http://www.skincancer.org/skin-cancer-information/basal-cell-carcinoma

Rogers, H. W., Weinstock, M. A., Harris, A. R., Hinckley, M. R., Feldman, S. R., Fleischer, A. B., & Coldiron, B. M. (2010). Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Archives of Dermatology, 146(3), 283–287. Doi:10.1001/archdermatol.2010.19

SOURCE Caliber Imaging & Diagnostics